Doripenem: a review of its use in the treatment of bacterial infections.
Doripenem, a parenteral, broad-spectrum antibacterial agent of the carbapenem family, is indicated as empirical therapy in serious bacterial infections in adults. Doripenem is indicated in Japan for use as a single agent in intra-abdominal infections (IAIs), lower respiratory tract infections (including nosocomial pneumonia), complicated urinary tract infections (cUTIs) and a variety of other bacterial infections, such as complicated skin and skin structure infections (cSSSIs), obstetric and gynaecological infections, serious ear, nose and throat infections, sepsis and endocarditis, dental and oral surgical infection, and ophthalmic infection caused by various susceptible strains of Gram-negative, Gram-positive or anaerobic bacteria. Doripenem is indicated in the US for the treatment of complicated IAIs (cIAIs) or cUTIs, including pyelonephritis, caused by susceptible strains of designated pathogens, and in the EU for the treatment of nosocomial pneumonia (including ventilator-associated pneumonia [VAP]), cIAIs or cUTIs.Doripenem has a broad spectrum of in vitro activity against Gram-positive and Gram-negative bacteria, including extended-spectrum beta-lactamase (ESBL)- and AmpC-producing Enterobacteriaceae, and anaerobic pathogens. The drug also has a low propensity to select for resistance and is suitable for the prolonged infusions that may be required to achieve pharmacodynamic/pharmacokinetic targets for bactericidal activity (and therefore efficacy) against pathogens with increased MICs (minimum concentrations required to inhibit the pathogens). Doripenem is no less effective than other antibacterial agents, including meropenem, imipenem/cilastin, piperacillin/tazobactam or levofloxacin in a wide range of serious bacterial infections, such as complicated lower respiratory infections, nosocomial pneumonia (including VAP), cIAIs and cUTIs, and is well tolerated. Thus, doripenem is a valuable addition to the options available for the empirical treatment of serious bacterial infections in hospitalized patients.
Keam
Susan J
SJ
Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015780:Carbapenems / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077726:Doripenem; D004347:Drug Interactions; D024881:Drug Resistance, Bacterial; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem
J Infect Chemother. 2002 Dec;8(4):371-3
12525903
Curr Med Res Opin. 2008 Jul;24(7):2113-26
18549664
Drugs. 2003;63(9):913-25; discussion 926
12678575
Clin Infect Dis. 2006 Sep 1;43 Suppl 2:S100-5
16894511
J Infect Chemother. 2005 Oct;11(5):259-61
16258825
J Antimicrob Chemother. 2005 Jun;55(6):965-73
15849262
J Antimicrob Chemother. 2008 Mar;61(3):751-3
18238882
Diagn Microbiol Infect Dis. 2007 Jan;57(1):85-91
16854555
Drugs. 2003;63(17):1855-78
12921489
Crit Care Med. 2008 Apr;36(4):1089-96
18379232
Drugs. 2000 Sep;60(3):619-46
11030471
Diagn Microbiol Infect Dis. 2005 May;52(1):71-4
15878447
Chemotherapy. 2000 May-Jun;46(3):184-7
10765033
Drugs. 2007;67(7):1027-52
17488146
Curr Opin Crit Care. 2004 Feb;10(1):59-64
15166851
Drugs. 2003;63(20):2157-68
14498753
Antimicrob Agents Chemother. 2006 Sep;50(9):3150-3
16940115
J Hepatobiliary Pancreat Surg. 2007;14(1):59-67
17252298
Antimicrob Agents Chemother. 2004 Apr;48(4):1384-96
15047550
Antimicrob Agents Chemother. 2004 Aug;48(8):3136-40
15273134
Mol Microbiol. 2005 Apr;56(2):309-22
15813726
Diagn Microbiol Infect Dis. 2006 Jul;55(3):241-3
16725297
Drugs. 1996 Jan;51(1):99-136
8741235
Clin Microbiol Infect. 2007 Jun;13(6):560-78
17266725
Drugs. 2008;68(6):803-38
18416587
Drugs. 2008;68(2):165-89
18197724
In Vivo. 2006 Jan-Feb;20(1):91-6
16433034
Drug Metab Dispos. 2004 Dec;32(12):1383-91
15345660
Toxicology. 2006 May 1;222(1-2):114-24
16549226
Clin Infect Dis. 2003 Oct 15;37(8):997-1005
14523762
Drugs. 2005;65(15):2151-78
16225376
Antimicrob Agents Chemother. 2004 Apr;48(4):1313-9
15047535
Clin Pharmacokinet. 2000 Sep;39(3):185-201
11020134
Antimicrob Agents Chemother. 2001 Apr;45(4):1284-6
11257048
Clin Ther. 2008 May;30(5):868-83
18555934
Jpn J Antibiot. 2005 Dec;58(6):489-506
16521342
J Antimicrob Chemother. 2007 Dec;60(6):1395-7
17884833
Drugs. 1995 Jul;50(1):73-101
7588092
Antimicrob Agents Chemother. 2004 Apr;48(4):1175-87
15047518
Eur Respir J. 2005 Dec;26(6):1138-80
16319346
Antimicrob Agents Chemother. 2005 Jun;49(6):2510-1
15917558
Antimicrob Agents Chemother. 2008 Apr;52(4):1510-2
18250190
Intern Med. 2006;45(7):419-28
16679695
Clin Ther. 2008 Apr;30(4):717-33
18498921
Antimicrob Agents Chemother. 2004 Aug;48(8):3086-92
15273124
J Antimicrob Chemother. 2006 Jul;58(1):37-46
16757501
J Antimicrob Chemother. 2000 Sep;46(3):471-4
10980177
J Chemother. 2002 Apr;14(2):155-60
12017370
J Antimicrob Chemother. 2004 Jul;54(1):144-54
15190031
Jpn J Antibiot. 2007 Dec;60(6):378-86
18447207
Antimicrob Agents Chemother. 2008 Feb;52(2):761-6
18070958
J Clin Microbiol. 2004 Nov;42(11):5256-63
15528723
N Engl J Med. 2008 Mar 20;358(12):1271-81
18354105
Clin Microbiol Infect. 2005 Dec;11(12):974-84
16307551
Antimicrob Agents Chemother. 2006 Feb;50(2):819-21
16436756
Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7
16127078
Microb Drug Resist. 2006 Winter;12(4):223-30
17227206
Expert Opin Pharmacother. 2008 Mar;9(4):561-75
18312158
Drugs. 2004;64(2):159-204
14717618
Chemotherapy. 2004;50 Suppl 1:3-10
15319548
Curr Opin Pharmacol. 2005 Oct;5(5):452-8
16084766
Antimicrob Agents Chemother. 2008 Jan;52(1):365-73
17938185
J Antimicrob Chemother. 1996 May;37(5):1034-6
8737157
Crit Care Med. 2008 Jan;36(1):296-327
18158437
Drugs. 2007;67(3):351-68
17335295
Respir Care. 2004 Dec;49(12):1530-41
15571647
Diagn Microbiol Infect Dis. 2007 Dec;59(4):467-72
17997070
Antimicrob Agents Chemother. 2005 Oct;49(10):4413-7
16189137
J Pharm Sci. 2008 Apr;97(4):1606-14
17705288
Drugs. 2000 Mar;59(3):653-80
10776838
Drugs. 2002;62(15):2221-34; discussion 2235
12381221
J Antimicrob Chemother. 2005 Jun;55(6):944-9
15872043
Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9
17517836
Clin Infect Dis. 2005 Nov 15;41(10):1373-406
16231249
Crit Care Clin. 2008 Apr;24(2):261-78, viii
18361945
Drug Metab Rev. 2007;39(4):647-57
18058328